Oral chemotherapy in colorectal cancer treatment: review of the literature.
Recent advances in anticancer treatment have focused on the development of oral anticancer agents with the intention of improving the patients' quality of life as well as providing therapeutic alternatives to intravenous chemotherapy. Until agents such as oxaliplatin and irinotecan became available, the treatment of colorectal cancer, one the most common cancers diagnosed in industralized countries, was mainly based on 5-fluorouracil modulation. The overwhelming majority of these new drugs are pyrimidine analogues intended to replace intravenous treatment or to make the therapy more acceptable to the patients. In this article, the use of oral chemotherapy, alone or in combination with radiotherapy, in colorectal cancer is reviewed and updated. The rationale for using oral compounds is discussed and newer agents, such as oral camptothecin analogues and antiangiogenic agents, are presented with the results of their clinical and preclinical developments.
Kurtz
Jean Emmanuel
JE
Departments of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Andrès
Emmanuel
E
Natarajan-Amé
Shanti
S
Noel
Esther
E
Dufour
Patrick
P